SHS Webinar on CMC strategy for early-stage Biotech / Pharma companies

This webinar will introduce you to key factors and the importance of investing in CMC development at the right time for early stage Biotech / Pharma companies. You will get definitions of CMC/Technical Development, Pharmaceutical TPP, essential drivers to make changes / investments, critical milestones for CMC in drug development and supply chain complexity.

Key take-aways will be:

• Identification of CMC milestones in different development phases

• Understanding of the importance to invest at the right time in CMC

• Considerations to avoid delays in drug development and increase asset value

Speaker

Rudolf Hausmann, Partner at Viopas Venture Consulting

Rudolf is a senior expert in chemistry, manufacturing and controls (CMC) technical development and production from API to finished product and technical operations with additional experience in clinical and commercial supply chain management and quality assurance. He has broad expertise in CMC areas of small molecules, biologics and peptides accumulated over 25 years in leadership positions the pharmaceutical industry in Big Pharma and emerging Pharma/Biotech companies.

About Viopas

Through extensive experience of their team of senior ​life-science experts ​with complimentary experience and ​broad networks, with presence in Zürich, Basel, Munich and Vienna, VVC offers a wide range of tailor-made services and advice to clients from the Healthcare industry. As entrepreneurs they combine scientific expertise, financial proficiency, and the know-how to successfully develop a healthcare business – they are not just advisors but true partners.